1. Home
  2. KPTI vs LSBK Comparison

KPTI vs LSBK Comparison

Compare KPTI & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • LSBK
  • Stock Information
  • Founded
  • KPTI 2008
  • LSBK 1891
  • Country
  • KPTI United States
  • LSBK United States
  • Employees
  • KPTI N/A
  • LSBK N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • LSBK Savings Institutions
  • Sector
  • KPTI Health Care
  • LSBK Finance
  • Exchange
  • KPTI Nasdaq
  • LSBK Nasdaq
  • Market Cap
  • KPTI 81.1M
  • LSBK 91.1M
  • IPO Year
  • KPTI 2013
  • LSBK 2006
  • Fundamental
  • Price
  • KPTI $0.62
  • LSBK $15.80
  • Analyst Decision
  • KPTI Strong Buy
  • LSBK
  • Analyst Count
  • KPTI 4
  • LSBK 0
  • Target Price
  • KPTI $5.00
  • LSBK N/A
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • LSBK 4.1K
  • Earning Date
  • KPTI 02-19-2025
  • LSBK 01-24-2025
  • Dividend Yield
  • KPTI N/A
  • LSBK 4.56%
  • EPS Growth
  • KPTI N/A
  • LSBK 7.32
  • EPS
  • KPTI N/A
  • LSBK 0.88
  • Revenue
  • KPTI $148,442,000.00
  • LSBK $25,846,000.00
  • Revenue This Year
  • KPTI $4.47
  • LSBK N/A
  • Revenue Next Year
  • KPTI $7.35
  • LSBK N/A
  • P/E Ratio
  • KPTI N/A
  • LSBK $17.95
  • Revenue Growth
  • KPTI 1.77
  • LSBK N/A
  • 52 Week Low
  • KPTI $0.58
  • LSBK $10.30
  • 52 Week High
  • KPTI $1.70
  • LSBK $16.56
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • LSBK 64.39
  • Support Level
  • KPTI $0.58
  • LSBK $15.51
  • Resistance Level
  • KPTI $0.67
  • LSBK $16.56
  • Average True Range (ATR)
  • KPTI 0.05
  • LSBK 0.42
  • MACD
  • KPTI -0.00
  • LSBK 0.08
  • Stochastic Oscillator
  • KPTI 31.02
  • LSBK 75.95

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

Share on Social Networks: